2Degli Esposti E, Sturani A, Di Martino M, et al. Long- acting persistence with antihypertensive medications in new patients[J ]. J Hum Hypertens, 2002, 16(6) :439 - 444.
3Dusing R, Weisser B, Mengden T, et al. Changes in antihypertensive therapy-the role of adverse effects and compliance[J ]. Blood Press, 1998, 7(5- 6) :313- 315.
4Marentette MA, Gerth WC, Billings DK, et al. Antihypertensive persistence and drug class[J]. Can J Cardiol, 2002, 18(6) :649 - 656.
5Morisky DE, Green I.W, l.evine DM. Concurrent and predictive validity of self- reported measure of medication adherence[J]. Mcd care,1986,24(1) :67-74.
6Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy : evidence from a meta - analysis[J]. Clin Ther, 2002, 24(2 ) : 302 -316.
7Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a veterans affairs heahhcare system[J]. Ann Pharmacother, 2002, 36 (6) :986 - 991.
8Salas M, In't Veld BA, van der Linden PD, et al. Impaired cognitive function and compliance with antihypertensive medications in elderly:the Rotterdam Study [ J ]. Clin Pharmacol Ther, 2001, 70 ( 6 ) : 561 -566.
二级参考文献4
1Miller NH, Hill M, Kottke T, et al. The multilevel compliance challenge;Recommendations for a call to action; a statement for healthcare professionals. Circulation, 1997; 95:1085
2Robert AK, George WV, Barry JM, et al. Safety of long-acting hydropyridine calcium channel blockers in hypertensive patients, Am J Cardiol, 1998, 81:163
3Murray E. Calcium channel blocker and hypertensive evolving perspectives-1996. Cardiovase Drugs Ther, 1997;10:883
4Prisant LM, Alpert BS, Robbing CB, et al. American national standard for nonautomated sphygmomanometers: summary reports. Am J Hypertens, 1995;8:210
